Product Launch

Phytopharm PLC
16 April 2007


Company Contact:                                U.K. Investor Relations Contact:
Phytopharm plc                                  FD
Dr Daryl Rees CEO                               David Yates
Mr Piers Morgan CFO                             Ben Atwell
[phone]                                [phone]
www.phytopharm.com



Launch of Phytopica(R) in France



GODMANCHESTER, Cambridgeshire, U.K. (16 April 2007) - Phytopharm plc (LSE: PYM)
('Phytopharm' or the 'Company') today announces the launch of Phytopica(R) in
France by its partner, Schering-Plough Animal Health ('Schering-Plough').  This
launch continues the European roll-out of Phytopica(R), which follows the launch
of Phytopica(R) in Italy last month.



In January 2006, Phytopharm entered into an exclusive global agreement with
Schering-Plough for the Company's canine skin health product, Phytopica(R).
Under the terms of the agreement, Phytopharm is responsible for manufacturing
Phytopica(R) whilst Schering-Plough is responsible for the global sales,
marketing and distribution of Phytopica(R).  In April 2006, Schering-Plough
launched Phytopica(R) in the UK and the product has enjoyed firm support from
veterinary dermatologists and recorded strong sales growth.



Phytopica(R) is effective in the management of canine skin health by providing a
novel 3 in 1 approach to help maintain a normal healthy immune system, support
normal white cell function and provide anti-oxidant benefits.  The beneficial
effects and excellent safety profile of Phytopica(R) have been proven
extensively in clinical trials and the product has been found to be suitable for
all dogs whatever size or breed.



With more than 8.5 million dogs, France is one of the largest companion animal
markets in Europe and of these, some 15% referred to veterinarians may be
affected by skin conditions.  Following the French launch, Schering-Plough will
seek to market and distribute Phytopica(R) in further countries worldwide.



Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer of
Phytopharm, said: 'We are delighted with the launch of Phytopica(R) in France by
one of the world's leading animal health companies.  Phytopica(R) sales in the
UK have exceeded our expectations and with Schering-Plough's European roll-out
now including France we look forward to further growth.



Commenting on today's announcement, Gildas Joalland, Companion Animal Manager at
Schering-Plough, France said: 'We are very pleased to be launching Phytopica(R)
in France as it offers a safe, easy to use and cost effective approach to the
long term management of canine skin health.  Following the success in the UK and
the increasing demand for safe and effective companion animal products in
France, we look forward to maximizing the potential of Phytopica(R).'



                                      -ENDS-



NOTES TO EDITORS


Phytopharm plc

Phytopharm is a pharmaceutical development and functional food company whose
product leads are generated from medicinal plants.  The Company's strategy is to
develop these products through 'proof of principle' clinical testing, and then
secure partners for late stage development, sales and marketing. Laboratory,
manufacturing and clinical work is outsourced to selected specialists, operating
under expert in-house management.  This operational structure allows access to
advanced research techniques whilst maintaining low fixed overheads and a lower
development cost structure.



Canine dermatological disorders are recognised by veterinarians to be a major
problem in small animal practice, with an estimated 15-30% of the global dog
population affected by skin conditions (Muller & Kirk's Small Animal
Dermatology, 6th Ed, 2000).



For further information about Phytopharm please see our website at http://
www.phytopharm.com


Phytopica(R) is a registered trade-mark of Phytopharm plc.


                      This information is provided by RNS
            The company news service from the London Stock Exchange            BWCUPMGQW